Abstract
Cognitive disorders are an important group of disorders affecting the brain for which currently used drugs are often of low efficacy and mainly of symptomatic value. There is increasing evidence suggesting that epigenetic changes in gene expression underlie cognitive disorders. Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs, that reverse epigenetic changes in gene expression. At present most work on epigenetic drugs focuses on two types of drugs: histone deacetylase (HDAC) inhibitors, and drugs targeting DNA methylation. This article describes the role of epigenetic drugs in treating cognitive disorders, focusing on Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Epigenetic drugs may improve the clinical management of patients with cognitive disorders.
Keywords: Cognitive, DNA methylation, epigenetic drug, histone deacetylase.
Current Pharmaceutical Design
Title:Epigenetic Drugs in Cognitive Disorders
Volume: 20 Issue: 11
Author(s): Jacob Peedicayil
Affiliation:
Keywords: Cognitive, DNA methylation, epigenetic drug, histone deacetylase.
Abstract: Cognitive disorders are an important group of disorders affecting the brain for which currently used drugs are often of low efficacy and mainly of symptomatic value. There is increasing evidence suggesting that epigenetic changes in gene expression underlie cognitive disorders. Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs, that reverse epigenetic changes in gene expression. At present most work on epigenetic drugs focuses on two types of drugs: histone deacetylase (HDAC) inhibitors, and drugs targeting DNA methylation. This article describes the role of epigenetic drugs in treating cognitive disorders, focusing on Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Epigenetic drugs may improve the clinical management of patients with cognitive disorders.
Export Options
About this article
Cite this article as:
Peedicayil Jacob, Epigenetic Drugs in Cognitive Disorders, Current Pharmaceutical Design 2014; 20 (11) . https://dx.doi.org/10.2174/13816128113199990526
DOI https://dx.doi.org/10.2174/13816128113199990526 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Application of Dual-Source CT Coronary Angiography in Type 2 Diabetic Patients with Symptomatic Coronary Heart Disease
Current Vascular Pharmacology Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
Current Medicinal Chemistry Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design Pharmacological Treatment of ADHD and the Short and Long Term Effects on Sleep
Current Pharmaceutical Design “The Tools of the Trade” – An Overview of the Pharmacology of the Endocannabinoid System
Current Pharmaceutical Design The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry The Role of ROS and RNS in Regulating Life and Death of Blood Monocytes
Current Pharmaceutical Design Nerve Injury Associated with Regional Anesthesia
Current Topics in Medicinal Chemistry Renal Blood Flow Dynamics in Inbred Rat Strains Provides Insight into Autoregulation
Current Vascular Pharmacology